Concerning the Pan-Cancer Tissue Test for OncotypeTM For patients with progressed, metastatic, headstrong, or repetitive cancer, the Oncotype MAPTM Pan-Cancer Tissue test may be a fast, exhaustive tumor profiling board that makes a difference with treatment choice. The Oncotype Outline test...
For patients with progressed, metastatic, headstrong, or repetitive cancer, the Oncotype MAPTM Pan-Cancer Tissue test may be a fast, exhaustive tumor profiling board that makes a difference with treatment choice. The Oncotype Outline test employments immunohistochemistry and next-generation sequencing with negligible tissue necessities to supply in-depth experiences into genomic changes in hundreds of cancer-related qualities, counting tumor changes, duplicate number variations, combinations, tumor change burden, microsatellite precariousness, and protein expression. conveying results in 3-5 trade days With noteworthy biomarkers connected to more than 100 evidence-based medicines, more than 45 combination treatments, and more than 650 dynamic clinical trial affiliations, the Oncotype Outline test report is as of now planned to back clinical choice making and give treatment choices for a assortment of strong tumor sorts.
Oncotype MAP is a tissue-based assay that produces results regarding the underlying biology of a patient's cancer and provides treatment and clinical trial choices," explains the definition of an oncotype map. By utilising the most potent medicines to target the patient's tumour biology, genomic data help doctors individualise and optimise oncology therapy.
The 21 genes include genes associated with proliferation (Ki67, STK15, BIRC5, CCNB1, MYBL2), metastasis (MMP11, CTSL2), HER2 (GRB7, HER2), sex hormones (ER, PGR, BCL2, SCUBE2, GSTM1, BAG1, CD68), and internal control genes (ACTB, GAPDH, GUS, RPLPO and TFRC)
Nonetheless, patients who fit into either of these groups may benefit from the Oncotype DX Test: was identified as having early-stage, invasive breast cancer that is both "human epidermal growth factor receptor negative" (HEGFR) and "oestrogen receptor positive" (ER+) (HER2-). lymph nodes not present and pre- or post-menopausal (N-)
A small portion of the tumour tissue that is taken from the patient during surgery is used for the test. The patient doesn't need to undergo any further surgery or procedures in order to receive the Oncotype DX Test.
The majority of outcomes are available 7 to 10 days after the tumour sample is received by the laboratory doing the analysis. The doctor will next go through the findings with the patient and develop a treatment strategy that is especially suitable for you.
The Oncotype DX breast DCIS score is a recent development in genomic testing. Ductal carcinoma in situ, a noninvasive type of stage 0 breast cancer, is the condition for which this test is indicated (DCIS). It may also be used to develop a treatment strategy unique to a patient's cancer. If Oncotype is the right choice for you, ask your doctor or other healthcare provider.
|Test Type||GeneCORE Oncotype MAP Panel 2|
GeneCORE Oncotype MAP Panel 2 (Pathology Test)
Within 24 hours*
Early check ups are always better than delayed ones. Safety, precaution & care is depicted from the several health checkups. Here, we present simple & comprehensive health packages for any kind of testing to ensure the early prescribed treatment to safeguard your health.